Groowe Groowe / Newsroom / SNY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SNY News

Sanofi American Depositary Shares (Each representing one-half of one ordinary share)

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

globenewswire.com
SNY

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

globenewswire.com
SNY

Communiqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé

globenewswire.com
SNY

COUR Pharma Announces Closing of $50 Million Series B

globenewswire.com
SNY PFE

Collibra Named Databricks' Governance Partner of the Year; Collibra and Databricks Deepening a Partnership to Ground Agentic AI in Governed Context

prnewswire.com
RIVN MA BABA UBER CMG ADI AMZN GOOG MSFT NVDA CRM PYPL IBM INTC ADBE NFLX HON GE BA CAT UNH PEP KO MCD COST WMT TMO ABBV XOM CVX JPM BAC WFC C GS MS DIS CMCSA VZ T SBUX NKE MDT AMGN GILD BMY PFE MRK JNJ PG LMT RTX GD LRCX MU AMD QCOM TXN AVGO AMAT KLAC ASML ENPH CRSP REGN VRTX BIIB AZN SNY LLY BNTX XCUR ALGN TDOC ZBRA ROKU UL

AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus

globenewswire.com
SNY PFE AMGN REGN

Next Generation Drug Conjugates Market Expected to Reach USD 42.55 Billion by 2035 | MarketsandMarkets™

globenewswire.com
AZN NVS ALNY GILD ABBV IONS SNY

Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

prnewswire.com
SNY

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

globenewswire.com
SNY

INTRACARE REBRANDS CLINICAL RESEARCH DIVISION AS "CAREON"

prnewswire.com
SNY